Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 65 points (-0.4%) at 16,380 as of Friday, Jan. 10, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,832 issues advancing vs. 1,123 declining with 123 unchanged.

The Diversified Services industry currently sits up 0.3% versus the S&P 500, which is down 0.2%. Top gainers within the industry include YY ( YY), up 3.1%, and Hertz Global Holdings ( HTZ), up 0.8%. On the negative front, top decliners within the industry include Western Union Company ( WU), down 1.4%, MasterCard Incorporated ( MA), down 1.3%, Priceline.com ( PCLN), down 0.8%, Paychex ( PAYX), down 0.7% and Visa ( V), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. URS Corporation ( URS) is one of the companies pushing the Diversified Services industry higher today. As of noon trading, URS Corporation is up $1.35 (2.6%) to $53.70 on heavy volume. Thus far, 467,307 shares of URS Corporation exchanged hands as compared to its average daily volume of 589,400 shares. The stock has ranged in price between $52.52-$53.76 after having opened the day at $52.60 as compared to the previous trading day's close of $52.35.

URS Corporation provides engineering, construction, and technical services to public agencies and private sector clients worldwide. URS Corporation has a market cap of $3.9 billion and is part of the services sector. The company has a P/E ratio of 12.9, below the S&P 500 P/E ratio of 17.7. Shares are down 1.2% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate URS Corporation a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates URS Corporation as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full URS Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Infoblox ( BLOX) is up $1.86 (5.2%) to $37.30 on average volume. Thus far, 571,273 shares of Infoblox exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $35.82-$37.37 after having opened the day at $35.92 as compared to the previous trading day's close of $35.44.

Infoblox Inc. develops, markets, and sells automated network control solutions worldwide. Its appliance-based solution combines real-time IP address management with the automation of network control, and network change and configuration management processes in physical and virtual appliances. Infoblox has a market cap of $1.9 billion and is part of the services sector. Shares are up 7.3% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Infoblox a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Infoblox as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Get the full Infoblox Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Myriad Genetics ( MYGN) is up $1.34 (6.0%) to $23.73 on average volume. Thus far, 1.5 million shares of Myriad Genetics exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $22.37-$23.81 after having opened the day at $22.38 as compared to the previous trading day's close of $22.39.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $1.6 billion and is part of the services sector. The company has a P/E ratio of 10.2, below the S&P 500 P/E ratio of 17.7. Shares are up 6.7% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts who rate Myriad Genetics a buy, 2 analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Myriad Genetics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the diversified services industry could consider iShares Dow Jones US Cons Services ( IYC) while those bearish on the diversified services industry could consider ProShares Ultra Short Consumer Sers ( SCC).

null